Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

The health and economic impacts of infant Group B Streptococcal (GBS) disease

FY 2021-22

Summary
Group B Streptococcus (GBS) disease, a bacterial infection often harmless in healthy adults, is the leading cause of serious blood and brain infections in newborns. Globally, around 18% of pregnant women carry the GBS bacteria in their genital and urinary tract which they can transmit to their baby during birth. Even with improvements in treatments, many infants with GBS disease die from infection and survivors often suffer long-term health consequences such as deafness, mental function delays or paralysis. Nearly 75% of GBS disease in newborns happens in the first week of life, known as "early-onset disease". To help limit early-onset GBS disease, pregnant women are tested for GBS bacteria when they are 35-37 weeks pregnant. Those who test positive, receive antibiotics during labour. Those who go into labour prematurely and do not have the opportunity to receive testing also receive antibiotics. The current strategy helps to reduce early cases of GBS disease, but it still misses some cases and fails to prevent disease in older babies who become infected later. Antibiotics may harm the mother and infant by damaging beneficial bacteria and can cause a reaction among mothers who are allergic. Vaccinating mothers with a GBS vaccine during pregnancy may be a potential solution to prevent GBS in their babies. To help Canadians make decisions about whether a vaccine will be better at preventing GBS and reducing healthcare costs, we need to have more information on the health burden of infant GBS and the effectiveness of current Canadian screening and treatment strategies. This study aims to fill this knowledge gap by reporting on the health consequences and total costs related to infant GBS disease, while also comparing current and future prevention strategies in terms of effectiveness and costs. Our results will give insight into the potential benefit of GBS vaccination during pregnancy, which will be useful for informing and supporting future vaccine recommendations.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458923
Name
Fakhraei Romina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
The health and economic impacts of infant Group B Streptococcal (GBS) disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Group B Streptococcal Disease; Health Administrative Data; Immunization; Intrapartum Antibiotic Prophylaxis; Maternal Vaccination; Perinatal Epidemiology; Vaccine
Abstract
Group B Streptococcus (GBS) disease, a bacterial infection often harmless in healthy adults, is the leading cause of serious blood and brain infections in newborns. Globally, around 18% of pregnant women carry the GBS bacteria in their genital and urinary tract which they can transmit to their baby during birth. Even with improvements in treatments, many infants with GBS disease die from infection and survivors often suffer long-term health consequences such as deafness, mental function delays or paralysis. Nearly 75% of GBS disease in newborns happens in the first week of life, known as "early-onset disease". To help limit early-onset GBS disease, pregnant women are tested for GBS bacteria when they are 35-37 weeks pregnant. Those who test positive, receive antibiotics during labour. Those who go into labour prematurely and do not have the opportunity to receive testing also receive antibiotics. The current strategy helps to reduce early cases of GBS disease, but it still misses some cases and fails to prevent disease in older babies who become infected later. Antibiotics may harm the mother and infant by damaging beneficial bacteria and can cause a reaction among mothers who are allergic. Vaccinating mothers with a GBS vaccine during pregnancy may be a potential solution to prevent GBS in their babies. To help Canadians make decisions about whether a vaccine will be better at preventing GBS and reducing healthcare costs, we need to have more information on the health burden of infant GBS and the effectiveness of current Canadian screening and treatment strategies. This study aims to fill this knowledge gap by reporting on the health consequences and total costs related to infant GBS disease, while also comparing current and future prevention strategies in terms of effectiveness and costs. Our results will give insight into the potential benefit of GBS vaccination during pregnancy, which will be useful for informing and supporting future vaccine recommendations.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Fakhraei, Romina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~